With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
A single-center prospective feasibility trial assessing accuracy of tissue sampling in detecting pathological complete response (pCR) to neoadjuvant systemic therapy in women with triple-negative or Her2(+) breast cancers was reported last month in Annals of Surgery. In 40 women receiving neoadjuvant therapy and tissue sampling prior to surgery, combined fine-needle aspiration with vacuum-assisted core biopsy was able to assess pCR rates with 98% accuracy and a 5% false-negative rate. These promising results have paved the way for a Phase 2 clinical trial currently enrolling women who will forgo surgery and proceed directly with radiation in cases of CR on tissue sampling alone. We’ve sure come along way since Dr. Halsted.